ClinicalTrials.Veeva

Menu
M

Monroe Biomedical Research | Monroe, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3841136
QCZ484
Ritonavir
Retatrutide
PF-07321332
Maridebart Cafraglutide
Tirzepatide
RO7790121
LY3549492
Lasmiditan

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

35 of 81 total trials
Locations recently updated

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in part...

Enrolling
Major Depressive Disorder
Behavioral: Psychological Support
Drug: CYB003

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3532226
Drug: LY3841136

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses i...

Active, not recruiting
Asthma
Drug: Placebo
Drug: AMG 691

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Enrolling
Obesity & Overweight
Other: Placebo
Drug: ERX1000

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For...

Enrolling
Plaque, Amyloid
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weig...

Enrolling
Overweight and/or Obesity
Nutrition Disorders
Drug: PF-08653944
Drug: PF-08653945

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting
Obesity
Drug: Retatrutide
Drug: Tirzepatide

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Active, not recruiting
Moderately to Severely Active Ulcerative Colitis
Drug: Afimkibart
Drug: Placebo
Locations recently updated

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling
Moderately to Severely Active Crohns Disease
Drug: Placebo
Drug: Afimkibart

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerativ...

Enrolling
Ulcerative Colitis
Drug: RO7837195 Matched Placebo
Drug: RO7837195

This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combin...

Enrolling
Hypercholesterolaemia
Drug: Inclisiran placebo
Drug: QCZ484 placebo

The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to pla...

Active, not recruiting
Influenza
Combination Product: CD388 Injection
Combination Product: Placebo

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at differe...

Active, not recruiting
Hypertension
Drug: QCZ484
Other: Saline

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

Trial sponsors

Lilly logo
Pfizer logo
Novartis logo
Amgen logo
BioNTech logo
Janssen (J&J Innovative Medicine) logo
Sanofi logo
Gilead Sciences logo
Indivior logo
Moderna logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems